Vlp Capture Assay
Vlp Capture Assay - Related Videos
05:15
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay
0 Views •
Cited by 2 •
2022
Here, we present a protocol to detect neutralization epitopes on antigen-displaying virus-like particles (VLPs). Immunoprecipitation of the human immunodeficiency virus (HIV)-derived VLPs is performed using envelope glycoproteins-specific monoclonal antibodies coupled to protein G-conjugated magnetic beads. Captured VLPs are subsequently subjected to SDS-PAGE and Western blot-analysis employing viral core protein Gag-specific antibodies.
02:14
Prey Capture Assay: A Method to Study the Prey Capture Behavior of Zebrafish Larva
0 Views •
2023
This video describes the prey capture assay. The video discusses the method to study prey capture behavior of zebrafish larvae after the laser ablation of specific neurons.
14:48
Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
0 Views •
Cited by 53 •
2012
An ELISA can be easily converted to a Luminex xMAP assay and, through the benefits of multiplexing, several antibodies can be screened simultaneously to identify an optimum antibody pair, resulting in increased sensitivity and dynamic range, while reducing assay cost.
04:27
The Virus-Like Particles Capture Assay: A Method to Isolate Antigen-Displaying VLPs from a Sample Using Neutralizing Antibody-Conjugated Magnetic Beads
0 Views •
2025
In this video, we demonstrate an immunoprecipitation assay, called the VLP capture assay, to isolate antigen-displaying virus-like particles, or VLPs, from a sample. The antigen binds with specific antibodies bound to magnetic beads, forming an immobilized antigen-antibody complex that is later separated and stored for further analysis.
04:32
Immunofluorescence Assay: A Method to Identify Tumor Cells Captured on a Medical Wire
0 Views •
2023
This video describes the technique of immunofluorescence staining of circulating tumor cells captured on a functionalized medical wire. The functionalized wire allows isolation of CTCs in vivo, directly from patient’s blood...
FAQs
Signal generation depends on a two-antibody arrangement. The immobilized capture antibody first retains VLPs through a surface feature, and a labeled detection antibody then binds a second accessible epitope. When both recognition events occur, the resulting signal can be related to particle abundance in the sample.
Using two recognition reagents adds a second molecular checkpoint to the measurement. The capture antibody binds a VLP surface feature, while the labeled detection antibody must recognize another accessible epitope. This arrangement links the measured signal to particles that present both antibody-recognized features, making surface organization and epitope accessibility important considerations in assay interpretation.
A positive assay signal indicates recognition of VLP-associated surface features and supports estimating particle abundance. It does not establish that the particle contains a complete viral genome, because VLPs are noninfectious structures that mimic virus organization without one. The assay is therefore useful for particle-level characterization and monitoring, rather than as a direct measure of genome completeness.
An assay workflow starts by immobilizing the capture antibody, then introducing a biological or manufacturing sample so VLPs can bind. A labeled detection antibody is added to recognize a second accessible epitope, and the resulting signal is measured. Relating that signal to particle abundance enables characterization or monitoring of the sample.
Biological samples and manufacturing samples are both relevant because the assay can provide particle-level information in each setting. Researchers may use it to characterize VLP preparations, monitor production, or assess quality. These uses make the technique valuable when consistency of particle levels must be followed across development or manufacturing work.
In vaccine research, the assay can help quantify VLP levels while preparations are being evaluated, providing information that supports consistency assessment. Those results can guide development of VLP-based vaccines and delivery systems by showing how particle abundance differs across samples or preparations. The method connects an immunoassay readout with practical decisions in biological product development.